← Back to Search

Laser Therapy

Alexandrite Laser for Hidradenitis Suppurativa

N/A
Waitlist Available
Research Sponsored by Wayne State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up monthly for 4 months, then once 2 months later(6 months total)
Awards & highlights

Study Summary

This trial will test the effectiveness of hair removal laser treatment for hidradenitis on one side of the body, with the other side serving as a control.

Eligible Conditions
  • Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~monthly for 4 months, then once 2 months later(6 months total)
This trial's timeline: 3 weeks for screening, Varies for treatment, and monthly for 4 months, then once 2 months later(6 months total) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HS-LASI
Secondary outcome measures
HiSCR

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment ArmExperimental Treatment1 Intervention
For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
Group II: Control ArmActive Control1 Intervention
For each patient, one side of the body will be treated with the Alexandrite laser (the treatment arm) and the other will not be treated to serve as control (the control arm). For example, if a patient has the disease in both axillae, one will treatment and the other control
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alexandrite Laser
2017
N/A
~30

Find a Location

Who is running the clinical trial?

Wayne State UniversityLead Sponsor
307 Previous Clinical Trials
108,434 Total Patients Enrolled
1 Trials studying Hidradenitis Suppurativa
32 Patients Enrolled for Hidradenitis Suppurativa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Tennessee
Arizona
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
Wayne State University Physician Group Dermatology
Recent research and studies
Dermatologic SurgeryJournal
Randomized Control Trial for the Treatment of Hidradenitis Suppurativa with a Neodymium-doped Yttrium Aluminium Garnet Laser
Tierney, Emily, Bassel H. Mahmoud, Camile Hexsel, David Ozog, and Iltefat Hamzavi. 2009. “Randomized Control Trial for the Treatment of Hidradenitis Suppurativa with a Neodymium-doped Yttrium Aluminium Garnet Laser”. Dermatologic Surgery. Ovid Technologies (Wolters Kluwer Health). doi:10.1111/j.1524-4725.2009.01214.x.
Journal of the American Academy of DermatologyJournal
Prospective Controlled Clinical and Histopathologic Study of Hidradenitis Suppurativa Treated with the Long-pulsed Neodymium:yttrium-aluminium-garnet Laser
Mahmoud, Bassel H., Emily Tierney, Camile L. Hexsel, John Pui, David M. Ozog, and Iltefat H. Hamzavi. 2010. “Prospective Controlled Clinical and Histopathologic Study of Hidradenitis Suppurativa Treated with the Long-pulsed Neodymium:yttrium-aluminium-garnet Laser”. Journal of the American Academy of Dermatology. Elsevier BV. doi:10.1016/j.jaad.2009.07.048.
Journal of the European Academy of Dermatology and VenereologyJournal
Hiscr (hidradenitis Suppurativa Clinical Response): A Novel Clinical Endpoint to Evaluate Therapeutic Outcomes in Patients with Hidradenitis Suppurativa from the Placebo‐controlled Portion of a Phase 2 Adalimumab Study
Kimball, A.B., J.M. Sobell, C.C. Zouboulis, Y. Gu, D.A. Williams, M. Sundaram, H.D. Teixeira, and G.B.E. Jemec. 2015. “Hiscr (hidradenitis Suppurativa Clinical Response): A Novel Clinical Endpoint to Evaluate Therapeutic Outcomes in Patients with Hidradenitis Suppurativa from the Placebo‐controlled Portion of a Phase 2 Adalimumab Study”. Journal of the European Academy of Dermatology and Venereology. Wiley. doi:10.1111/jdv.13216.
clinicaltrials.govStudy
Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser
Steven D Daveluy 2017. "Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03054155.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top